What changed in the Feb 26, 2026 RHHBY analyst rating?

On Feb 26, 2026 Wolfe Research maintained an Outperform on Roche. The note added product pricing of $150 per genome and a mid-2026 launch but did not change the price target.

Does the Wolfe note include a new RHHBY price target?

No. Wolfe Research did not publish a new RHHBY price target when it maintained its Outperform on Feb 26, 2026. The note focused on consumables pricing and launch timing.

How should investors interpret the maintained RHHBY analyst rating?

A maintained rating signals continued analyst confidence, not a fresh upgrade. Investors should monitor launch execution, revenue signals, and guidance for any reassessment of RHHBY risk and reward.

How does Meyka AI view the RHHBY analyst rating update?

Meyka AI views the note as confirmation of existing upside potential and assigns RHHBY a grade of B+. This grade reflects benchmark comparison, sector trends, growth, metrics, and analyst consensus.

Analyst Ratings

Wolfe Maintains Outperform on Roche Holding AG (RHHBY) Feb 26, 2026

ByDanny Kontos March 2, 2026March 2, 2026

On Feb 26, 2026 Wolfe Research maintained an Outperform on Roche Holding AG, the key fact driving today’s RHHBY analyst rating coverage. Wolfe flagged consumables pricing at $150 per genome and a mid-2026 launch for certain products. This note keeps Wolfe’s positive stance without a price target revision. Roche’s market cap stands at $384,392,195,064, a reminder of scale behind Wolfe’s view.